



Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area  
Dehradun, Uttarakhand 248 110, India  
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,  
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India  
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

February 5, 2026

To  
Listing / Compliance Department  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai – 400 001

To  
Listing / Compliance Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**BSE CODE: 543329**

**NSE SYMBOL: WINDLAS**

Dear Sir/ Madam,

**Ref:** Compliance of Regulation 33 and Regulation 30 of the SEBI (LODR) Regulations, 2015.

**Sub: Outcome of the Board Meeting held on February 5, 2026**

We wish to inform you that the Board of Directors at its Meeting held on **Thursday, February 5, 2026**, approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025.

In this regard we enclose the following:

- i. Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025.
- ii. Limited Review Report of the Auditors on Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025.

The meeting of the Board of Directors commenced at 4.00 P.M. and concluded at 5.20 P.M.

Kindly take the same on record.

Thanking you,

Yours faithfully,

**For Windlas Biotech Limited**

Ananta Narayan Panda  
**Company Secretary & Compliance Officer**

**Encl:** as above

**J. C. BHALLA & CO.**  
CHARTERED ACCOUNTANTS

BRANCH OFFICE : B-5, SECTOR-6, NOIDA - 201 301 (U.P.)  
TEL. : +91 - 120 - 4241000, FAX : +91-120-4241007  
E-MAIL : taxaid@jcbhalla.com

**Independent Auditor's Limited Review Report on the Quarterly Consolidated Unaudited Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015, as amended**

To,  
The Board of Directors  
Windlas Biotech Limited

1. We have reviewed the accompanying statement of Consolidated Unaudited financial results ("the Statement") of Windlas Biotech Limited (hereinafter referred to as the "Parent") and its subsidiary (parent and its subsidiary together referred to as "the Group") for the quarter and nine months ended December 31, 2025, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34, "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 ("the Act") read with the relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statements includes the results of the following entities:

(a) Subsidiary

Windlas Inc., USA



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results include the financial results of one subsidiary which have not been reviewed by their auditors, whose financial results reflect, total revenue of Rs. 0.48 million and Rs. 0.48 million, net profit after tax of Rs. 0.49 million and Rs. 0.46 million and total comprehensive income of Rs. 0.49 million and Rs. 0.46 million for the quarter and nine months ended December 31, 2025 respectively. These unaudited financial results have been furnished to us by the Board of directors. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on such unreviewed/unaudited financial results. According to the information and explanations given to us by the Management, these financial results are not material to the Group.

Our conclusion on the statement is not modified in respect of the above matter.

#### 7. Other Matter

The comparative financial information of the Group for the quarter and nine months ended December 31, 2024 and year ended March 31, 2025 prepared in accordance with Ind AS included in this Statement have been reviewed/ audited, as applicable, by the predecessor auditors. The reports of the predecessor auditors on this comparative financial information dated February 11, 2025 and May 22, 2025 respectively, expressed an unmodified conclusion/ opinion, as applicable. Our conclusion on the Statement is not modified in respect of above matter.

For J C Bhalla & Co.  
Chartered Accountants  
Firm Regn. no. - 001111N



Anshuman Mallick  
Partner

Membership No. - 547705

UDIN: 26547705JFQCYP1327

Place: Noida

Date : February 05, 2026

**Windlas Biotech Limited**  
**CIN: L74899UR2001PLC033407**  
**Registered office: 40/1 Mohabewala Industrial Area, SBI Road, Dehradun-248110 (Uttarakhand), India**  
**Telephone No: 0135-6608000| Email ID: cs@windlasbiotech.com| Website: www.windlasbiotech.com**  
**Statement of Consolidated unaudited financial results for the quarter and nine months ended 31st December'2025**  
**(All amounts in Indian Rupees in millions, unless otherwise stated)**

Particulars	Quarter Ended			Nine months ended		Year Ended
	31st December, 2025 (Unaudited)	30th September, 2025 (Unaudited)	31st December, 2024 (Unaudited)	31st December, 2025 (Unaudited)	31st December, 2024 (Unaudited)	31st March, 2025 (Audited)
Revenue from Operations	2,331.02	2,223.98	1,950.19	6,655.90	5,571.73	7,598.78
Other Income	45.70	36.45	41.07	134.54	130.81	180.18
<b>Total Income</b>	<b>2,376.72</b>	<b>2,260.43</b>	<b>1,991.26</b>	<b>6,790.44</b>	<b>5,702.54</b>	<b>7,778.96</b>
<b>Expenses</b>						
Cost of Material Consumed	1,349.26	1,442.87	1,345.13	4,046.67	3,782.82	4,933.78
Changes in Inventories of Finished goods and Work-in-progress	85.75	(73.35)	(136.81)	55.16	(316.18)	(215.23)
Employee Benefit Expenses	420.48	364.45	321.72	1,107.24	909.89	1,229.16
Finance Cost	12.77	10.16	14.60	33.51	30.55	43.82
Depreciation and Amortization expense	76.99	75.97	69.39	227.44	196.50	279.85
Other Expenses	231.76	204.45	173.85	652.26	509.61	710.00
<b>Total Expenses</b>	<b>2,177.01</b>	<b>2,024.55</b>	<b>1,787.88</b>	<b>6,122.28</b>	<b>5,113.19</b>	<b>6,981.38</b>
<b>Profit before share of gain / loss in joint venture</b>	<b>199.71</b>	<b>235.88</b>	<b>203.38</b>	<b>668.16</b>	<b>589.35</b>	<b>797.58</b>
Share of gain/(loss) in joint venture	-	-	-	-	-	-
<b>Profit before tax</b>	<b>199.71</b>	<b>235.88</b>	<b>203.38</b>	<b>668.16</b>	<b>589.35</b>	<b>797.58</b>
<b>Income tax expense</b>						
Current tax	44.60	58.76	39.42	158.89	136.86	182.92
Deferred Tax	5.09	(0.88)	8.20	4.61	5.36	4.72
<b>Total Tax Expense</b>	<b>49.69</b>	<b>57.88</b>	<b>47.62</b>	<b>163.50</b>	<b>142.22</b>	<b>187.64</b>
<b>Profit for the year</b>	<b>150.02</b>	<b>178.00</b>	<b>155.76</b>	<b>504.66</b>	<b>447.13</b>	<b>609.94</b>
<b>Profit attributable to Owners'</b>	<b>150.02</b>	<b>178.00</b>	<b>155.76</b>	<b>504.66</b>	<b>447.13</b>	<b>609.94</b>
<b>Profit attributable to Non Controlling Interest</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Other Comprehensive Income</b>						
A (i) Items that will not be reclassified to profit or loss:						
Remeasurement of defined benefit plans- gain/(loss)	2.30	(2.33)	(0.43)	0.45	(9.59)	(7.26)
Income tax effect	(0.58)	0.59	0.10	(0.11)	2.41	1.83
B (i) Items that will be reclassified to profit or loss:						
Foreign currency translation reserve	0.01	(0.02)	0.12	(0.02)	0.10	(0.06)
<b>Other Comprehensive Income for the year</b>	<b>1.73</b>	<b>(1.76)</b>	<b>(0.21)</b>	<b>0.32</b>	<b>(7.08)</b>	<b>(5.49)</b>
<b>Total Comprehensive Income for the year</b>	<b>151.75</b>	<b>176.24</b>	<b>155.55</b>	<b>504.98</b>	<b>440.05</b>	<b>604.45</b>
<b>Other Comprehensive Income attributable to Owner's</b>	<b>1.73</b>	<b>(1.76)</b>	<b>(0.21)</b>	<b>0.32</b>	<b>(7.08)</b>	<b>(5.49)</b>
<b>Other Comprehensive Income attributable to Non Controlling Interest</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total Comprehensive Income attributable to Owner's</b>	<b>151.75</b>	<b>176.24</b>	<b>155.55</b>	<b>504.98</b>	<b>440.05</b>	<b>604.45</b>
<b>Total Comprehensive Income attributable to Non Controlling Interest</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Paid up equity share capital (Face value of Rs. 5/- per share)	105.39	105.39	104.50	105.39	104.50	104.80
<b>Total Reserves</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4,952.92</b>
<b>Earnings per share*:</b>						
Basic (in Rs.)	7.12	8.48	7.45	24.02	21.42	29.19
Diluted (in Rs.)	7.05	8.40	7.38	23.77	21.20	28.87
Face value per share (in Rs)	5.00	5.00	5.00	5.00	5.00	5.00

\*EPS are not annualised

**Notes :**

- The consolidated unaudited financial results of Windlas Biotech Limited ("the Holding Company") together with its subsidiary (parent and its subsidiary together referred to as "the Group") for the quarter and nine months ended as on December 31, 2025 have been prepared as per regulation 33 of the SEBI LODR (Listing Obligation and Disclosure Requirements ) regulation 2015.
- The consolidated financial results of the Group have been reviewed by the audit committee and approved by the board of directors at their meetings held on February 5, 2026 and limited review has been carried out by statutory auditor of the Company.
- The financial results of the Group have been prepared in accordance with the Indian Accounting Standard notified under section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended.
- According to Indian Accounting Standards (Ind-AS) 108 on "Operating Segment" the Group has only one primarily reportable segment i.e. "Pharmaceuticals"
- During the current year, the Holding Company has allotted 117928 equity shares of Rs. 5 each under the ESOP schemes of the Holding Company to eligible employees. Accordingly, the share capital has increased from Rs. 104.80 million to 105.39 million. Further, the Holding Company has recorded cost of Rs. 93.53 million for the period ended December 31, 2025 (Rs. 24.60 million for the year ended March 31, 2025).

**Windlas Biotech Limited**

**CIN: L74899UR2001PLC033407**

**Registered office: 40/1 Mohabewala Industrial Area, SBI Road, Dehradun-248110 (Uttarakhand), India**

**Telephone No: 0135-6608000| Email ID: cs@windlasbiotech.com| Website: www.windlasbiotech.com**

**Statement of Consolidated unaudited financial results for the quarter and nine months ended 31st December'2025**

**(All amounts in Indian Rupees in millions, unless otherwise stated)**

6. During the period ended December 31, 2025, the Holding Company has introduced 'Windlas Plan 2025' to grant not exceeding 590,250 options / units to the eligible employees exercisable into equity shares of face value Rs. 5 each fully paid up. The Holding Company has obtained approval for the scheme from board of directors on May 22, 2025 and shareholders' approval on July 28, 2025. Further, the Holding Company has also received In-Principle approval from Stock Exchanges namely National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange of India Limited (BSE) on September 9, 2025. As on September 15, 2025, the Holding Company has granted 570,500 options / units with exercise price of Rs. 5 after taking approval of Nomination and Remuneration Committee of Directors.

7. The consolidated figures for the quarter ended December 31, 2025 are the balancing figure between the unaudited figures in respect of the period ended December 31, 2025 and the published unaudited figures for the six months ended September 30, 2025, which were subject to a limited review by the statutory auditors.

8. During the period ended December 31, 2025, the Holding Company has paid final dividend of Rs. 5.80 per share for the financial year 2024-25, as approved in the annual general meeting held on July 28, 2025. The aggregate dividend payout to shareholders amounted to Rs. 121.56 million.

9. During the year ended March 31, 2025, Windlas Inc. ( a Wholly Owned Subsidiary) has assigned its 50% share in its Joint Venture namely, USpharma Windlas LLC to US Pharma Ltd. without consideration via agreement dated July 12, 2024. Therefore, USpharma Windlas LLC has ceased to be a joint Venture of the Holding Company.

10. The Government of India has consolidated 29 existing labour legislations into four labour codes (collectively referred to as the "Codes"), which became effective from November 21, 2025. The Ministry of Labour & Employment has issued draft Central Rules and FAQs to facilitate assessment of the financial impact of these changes. The Group has evaluated the impact of the Codes based on the information currently available and the guidance issued by the Institute of Chartered Accountants of India and has concluded that there is no material impact on the consolidated financial results for the quarter and nine months ended December 31, 2025. The Group will continue to monitor developments relating to the notification of Central and State Rules and assess the impact, if any, in future periods.

11. The Board of the Holding Company in its meeting held on February 5, 2026, has approved the closure/ dissolution of Windlas Inc. USA, the non operative wholly owned subsidiary Company. The application for dissolution shall be initiated as per the laws of Delaware, USA.

**For and on behalf of the board of directors of Windlas Biotech Limited**



**Hitesh Windlass  
Managing Director  
DIN: 02030941**

**Place: Gurugram**

**Date: February 5, 2026**

**J. C. BHALLA & CO.**  
CHARTERED ACCOUNTANTS

BRANCH OFFICE : B-5, SECTOR-6, NOIDA - 201 301 (U.P.)  
TEL. : +91 - 120 - 4241000, FAX : +91-120-4241007  
E-MAIL : taxaid@jcbhalla.com

**Independent Auditor's Limited Review Report on the Quarterly Standalone Unaudited Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended**

To,  
The Board of Directors  
Windlas Biotech Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ("the Statement") of Windlas Biotech Limited ("the Company") for the quarter and nine months ended December 31, 2025, attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended'
2. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. The preparation of the statement is in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with the applicable Indian Accounting Standards (Ind-AS) prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



5. Other Matter

The comparative financial information of the Company for the quarter and nine months ended December 31, 2024 and year ended March 31, 2025 prepared in accordance with Ind AS included in this Statement have been reviewed/audited, as applicable, by the predecessor auditors. The reports of the predecessor auditors on this comparative financial information dated February 11, 2025 and May 22, 2025 respectively, expressed an unmodified conclusion/opinion, as applicable. Our conclusion on the Statement is not modified in respect of above matter.

For J C Bhalla & Co.  
Chartered Accountants  
Firm Regn. no. - 001111N



Anshuman Mallick  
Partner  
Membership No. - 547705  
UDIN: 26547705J2KXWL5747

Place: Noida  
Date : February 05, 2026



**Windlas Biotech Limited**  
CIN: L74899UR2001PLC033407  
Registered office: 40/1 Mohabewala Industrial Area, SBI Road, Dehradun-248110 (Uttarakhand), India  
Telephone No: 0135-6608000 | Email ID: cs@windlasbiotech.com | Website: www.windlasbiotech.com  
Statement of Standalone unaudited financial results for the quarter and nine months ended 31st December'2025  
(All amounts in Indian Rupees in millions, unless otherwise stated)

Particulars	Quarter Ended			Nine months ended		Year Ended
	31st December, 2025 (Unaudited)	30th September, 2025 (Unaudited)	31st December, 2024 (Unaudited)	31st December, 2025 (Unaudited)	31st December, 2024 (Unaudited)	31st March, 2025 (Audited)
Revenue from Operations	2,331.02	2,223.98	1,950.19	6,655.90	5,571.73	7,598.78
Other Income	45.22	36.45	37.31	134.06	127.05	176.46
<b>Total Income</b>	<b>2,376.24</b>	<b>2,260.43</b>	<b>1,987.50</b>	<b>6,789.96</b>	<b>5,698.78</b>	<b>7,775.24</b>
<b>Expenses</b>						
Cost of Material Consumed	1,349.26	1,442.87	1,345.13	4,046.67	3,782.82	4,933.78
Changes in Inventories of Finished goods and Work-in-progress	85.75	(73.35)	(136.81)	55.16	(316.18)	(215.23)
Employee Benefit Expenses	420.48	364.45	321.72	1,107.24	909.89	1,229.16
Finance Cost	12.77	10.16	14.60	33.50	30.55	43.82
Depreciation and Amortization expense	76.99	75.97	69.39	227.44	196.50	279.85
Other Expenses	231.76	204.45	173.77	652.26	509.53	709.92
<b>Total Expenses</b>	<b>2,177.01</b>	<b>2,024.55</b>	<b>1,787.80</b>	<b>6,122.27</b>	<b>5,113.11</b>	<b>6,981.30</b>
<b>Profit before tax</b>	<b>199.23</b>	<b>235.88</b>	<b>199.70</b>	<b>667.69</b>	<b>585.67</b>	<b>793.94</b>
<b>Income tax expense</b>						
Current tax	44.60	58.76	39.23	158.89	136.67	182.73
Deferred Tax	5.09	(0.88)	8.20	4.61	5.36	4.72
<b>Total Tax Expense</b>	<b>49.69</b>	<b>57.88</b>	<b>47.43</b>	<b>163.50</b>	<b>142.03</b>	<b>187.45</b>
<b>Profit for the year</b>	<b>149.54</b>	<b>178.00</b>	<b>152.27</b>	<b>504.19</b>	<b>443.64</b>	<b>606.49</b>
<b>Other Comprehensive Income</b>						
A (i) Items that will not be reclassified to profit or loss:						
Remeasurement of defined benefit plans- gain/(loss)	2.30	(2.33)	(0.43)	0.45	(9.59)	(7.26)
Income tax effect	(0.58)	0.59	0.10	(0.11)	2.41	1.83
<b>Other Comprehensive Income for the year</b>	<b>1.72</b>	<b>(1.74)</b>	<b>(0.33)</b>	<b>0.34</b>	<b>(7.18)</b>	<b>(5.43)</b>
<b>Total Comprehensive Income for the year</b>	<b>151.26</b>	<b>176.26</b>	<b>151.94</b>	<b>504.53</b>	<b>436.46</b>	<b>601.06</b>
Paid up equity share capital (Face value of Rs. 5/- per share)	105.39	105.39	104.50	105.39	104.50	104.80
<b>Total Reserves</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4,953.08</b>
<b>Earnings per share*:</b>						
Basic (in Rs.)	7.09	8.48	7.29	24.00	21.25	29.03
Diluted (in Rs.)	7.03	8.40	7.21	23.75	21.03	28.71
Face value per share (in Rs)	5.00	5.00	5.00	5.00	5.00	5.00

\*EPS are not annualised

**Notes :**

- The standalone unaudited financial results of Windlas Biotech Limited ("the Company") for the quarter and nine months ended as on December 31, 2025 have been prepared as per regulation 33 of the SEBI LODR (Listing Obligation and Disclosure Requirements) regulation 2015.
- The standalone financial results of the Company have been reviewed by the audit committee and approved by the board of directors at their meetings held on February 5, 2026 and limited review has been carried out by statutory auditor.
- The financial results of the Company have been prepared in accordance with the Indian Accounting Standard notified under section 133 of the companies act, 2013, read with the companies (Indian accounting standards) Rules, 2015, as amended.
- According to Indian Accounting Standards (Ind-AS) 108 on "Operating Segment" the Company has only one primarily reportable segment i.e. "Pharmaceuticals"
- During the current year, the company has allotted 117928 equity shares of Rs. 5 each under the ESOP schemes of the company to eligible employees. Accordingly, the share capital has increased from Rs. 104.80 million to 105.39 million. Further, the company has recorded cost of Rs. 93.53 million for the period ended December 31, 2025 (Rs. 24.60 million for the year ended March 31, 2025).
- During the period ended December 31, 2025, the Company has introduced 'Windlas Plan 2025' to grant not exceeding 590,250 options / units to the eligible employees exercisable into equity shares of face value Rs. 5 each fully paid up. The Company has obtained approval for the scheme from board of directors on May 22, 2025 and shareholders' approval on July 28, 2025. Further, the Company has also received In-Principle approval from Stock Exchanges namely National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange of India Limited (BSE) on September 9, 2025. As on September 15, 2025, the Company has granted 570,500 options / units with exercise price of Rs. 5 after taking approval of Nomination and Remuneration Committee of Directors.
- The standalone figures for the quarter ended December 31, 2025 are the balancing figure between the unaudited figures in respect of the period ended December 31, 2025 and the published unaudited figures for the six months ended September 30, 2025, which were subject to a limited review by the statutory auditors.

**Windlas Biotech Limited**

**CIN: L74899UR2001PLC033407**

**Registered office: 40/1 Mohabewala Industrial Area, SBI Road, Dehradun-248110 (Uttarakhand), India**

**Telephone No: 0135-6608000 | Email ID: cs@windlasbiotech.com | Website: www.windlasbiotech.com**

**Statement of Standalone unaudited financial results for the quarter and nine months ended 31st December'2025**

**(All amounts in Indian Rupees in millions, unless otherwise stated)**

8. During the period ended December 31, 2025, the Company has paid final dividend of Rs. 5.80 per share for the financial year 2024-25, as approved in the annual general meeting held on July 28, 2025. The aggregate dividend payout to shareholders amounted to Rs. 121.56 million.

9. The Government of India has consolidated 29 existing labour legislations into four labour codes (collectively referred to as the "Codes"), which became effective from November 21, 2025. The Ministry of Labour & Employment has issued draft Central Rules and FAQs to facilitate assessment of the financial impact of these changes. The Company has evaluated the impact of the Codes based on the information currently available and the guidance issued by the Institute of Chartered Accountants of India and has concluded that there is no material impact on the standalone financial results for the quarter and nine months ended December 31, 2025. The Company will continue to monitor developments relating to the notification of Central and State Rules and assess the impact, if any, in future periods.

10. The Board in its meeting held on February 5, 2026, has approved the closure/ dissolution of Windlas Inc. USA, the non operative wholly owned subsidiary Company. The application for dissolution shall be initiated as per the laws of Delaware, USA.

**For and on behalf of the board of directors of Windlas Biotech Limited**



**Hitesh Windlass**  
**Managing Director**  
**DIN: 02030941**

**Place: Gurugram**

**Date: February 5, 2026**